Peer-Reviewed Study Validates BrainCheck’s Digital Cognitive Test, Signaling Breakthrough for Future of Dementia Diagnosis
BrainCheck, creator of the comprehensive cognitive assessment and care management platform for physicians, has announced the publication of a peer-reviewed study in the Journal of Medical Internet Research (JMIR) Aging: “A Computerized Cognitive Test Battery for Detection of Dementia and Mild Cognitive Impairment: Instrument Validation Study.”
Led by Reza Hosseini Ghomi, MD, MSE, who, at the time of the study, was a neuropsychiatrist and faculty member at the University of Washington Medicine Memory and Brain Wellness Center, the study validates the diagnostic accuracy of the BrainCheck computerized cognitive testing platform. The study found that BrainCheck was able to correctly distinguish between three levels of cognitive performance, including diagnosing dementia, mild cognitive impairment (MCI), and normal cognition (NC).
“The findings from this latest study, published in JMIR Aging, are a major step forward for dementia diagnosis and treatment,” says Ghomi, now chief medical officer of BrainCheck. “BrainCheck is committed to transforming the approach to cognitive care. By providing remote and clinic-based digital testing, the company is democratizing access to care, and offering providers the tools and resources they need to better diagnose and treat patients.”
Early dementia detection, intervention, and care planning help more patients live better and safer lives, decrease caregiver frustration and save health systems billions of dollars. Remote testing through digitally enabled tools makes cognitive assessments more accessible and removes common barriers in the patient journey.
Study participants had all previously been diagnosed with dementia, MCI or NC and were asked to complete the BrainCheck battery to compare the resulting diagnosis. The study concluded that “BrainCheck was able to distinguish between diagnoses of dementia, MCI, and NC, providing a reliable tool for the detection of early cognitive impairment.” Importantly, remote administration performed similarly to in-person testing. This study was among the first to validate a digital tool for the identification of MCI, which is notoriously hard to detect. Several studies are planned to start this year to further validate this finding.
BrainCheck is automated and quick to administer, both in-person and remotely, which improves accessibility to testing and enables early detection of cognitive decline, a particularly prevalent issue within the United States, where one in 10 people aged 65 and older have Alzheimer’s dementia, and an estimated 13.8 million Americans are projected to have Alzheimer’s dementia by 2050, according to the Alzheimer’s Association. This initial study paves the way for a comprehensive longitudinal study, exploring BrainCheck in early detection of dementia and monitoring of cognitive symptoms over time, including further comparison to gold-standard neuropsychological assessments.
For medical professionals interested to learn more about BrainCheck and request a demo, visit braincheck.com.